Posts

VectorY raises $83.5 million to advance experimental neurodegenerative-disease therapies

on
On November 11, 2026, Amsterdam-based VectorY Therapeutics announced €74.5 million ($83.5 million) in new financing to advance its antibody gene-therapy pipeline for neurodegenerative diseases. The financing adds to the company’s Series A. New participants include Angelini Ventures, Invest-NL, and the European Investment Bank (EIB); returning backers include Forbion, EQT Life Sciences, MRL Ventures, Insight Partners, BioGeneration Ventures, Eli Lilly, and the ALS Investment Fund. A €30 million EIB convertible loan is part of the financing and is supported by the European Commission’s InvestEU program. The main funding priority is VTx-002, VectorY’s experimental ALS therapy, through milestones in the PIONEER-ALS Phase 1/2 study, including its final readout. The trial is evaluating safety, tolerability, and preliminary activity; it is not yet established that the therapy works. VTx-002 uses a viral vector to deliver genetic instructions so cells in the central nervous system can ...

FDA approves Merck’s Abbisko-licensed drug for rare joint tumor

on

Capricor and NextCure disclose layoffs amid FDA review and merger preparations

on

FDA requires rare eye-condition warning on GLP-1 drug labels

on

Flagship combines Valo and Montai

on

PepGen’s early Phase 2 data lift shares as Ionis and ImmunityBio fall

on

Beam reports positive Phase 1/2 results for base-edited sickle cell therapy

on

Democrats step up scrutiny of confidential MFN drug deals

on

aTyr Pharma files to sell up to $80 million in stock

on

iORGANBIO and Mitsui Chemicals team up on AI-driven cell and organoid manufacturing

on

FDA investigates tumor reports linked to Zolgensma

on

argenx to acquire Unnatural Products for up to $1.15 billion

on

Hims & Hers and Eli Lilly agree to offer branded weight-loss drugs

on